AbCellera BiologicsABCL
About: AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Employees: 596
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
138% more call options, than puts
Call options by funds: $2.39M | Put options by funds: $1.01M
32% more capital invested
Capital invested by funds: $279M [Q1] → $368M (+$89.2M) [Q2]
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
2% less funds holding
Funds holding: 127 [Q1] → 125 (-2) [Q2]
6.05% less ownership
Funds ownership: 41.84% [Q1] → 35.8% (-6.05%) [Q2]
23% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 44
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Stifel Stephen Willey | 60%upside $7 | Buy Maintained | 8 Aug 2025 |
Keybanc Scott Schoenhaus | 129%upside $10 | Overweight Maintained | 14 Jul 2025 |
Leerink Partners Faisal Khurshid | 14%upside $5 | Outperform Assumed | 7 Jul 2025 |
Financial journalist opinion
Based on 5 articles about ABCL published over the past 30 days
